<p>/PRNewswire/ -- Avidity Biosciences, Inc.（&#34;Avidity&#34;）（纳斯达克：RNA）是一家生物制药公司，致力于提供一种新的 RNA 治疗药物类别，称为抗体寡核苷酸结合物（&#34;AOCs™&#34;），以深刻改善人们的生活。今天宣布，其董事会已指定 2026 年 2 月 12 日东部时间营业结束时为记录日期（&#34;记录日期&#34;），用于按比例分配 Atrium Therapeutics, Inc.（&#34;SpinCo&#34;）所有已发行和流通的普通股给在记录日期持有 Avidity 普通股的股东，这与之前宣布的 Avidity 被诺华制药（&#34;Merger&#34;）收购的提议以及将 Avidity 的早期精准心脏病项目分拆到 SpinCo（&#34;Spin-Off&#34;）有关。每位股东将在记录日期持有的每十股 Avidity 普通股中获得一股 SpinCo 普通股。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/974628/Avidity_Biosciences_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/974628/Avidity_Biosciences_Logo.jpg"/></p>
<p>合并和分拆的完成仍需满足 Avidity 于 2026 年 1 月 30 日向证券交易委员会提交的最终代理声明中提到的某些成交条件，包括获得 Avidity 股东的批准。因此，记录日期可能会根据合并和分拆的成交日期而变化。</p>
<p><strong>关于 Avidity</strong></p>
<p>Avidity Biosciences, Inc.的使命是通过提供一种新的 RNA 治疗药物类别——抗体寡核苷酸结合物（AOCs™）来深刻改善人们的生活。Avidity 正在通过其专有的 AOCs 革命性地改变 RNA 领域，这些 AOCs 旨在将单克隆抗体的特异性与寡核苷酸疗法的精准性结合起来，以应对以前无法通过现有 RNA 疗法达到的靶点和疾病。利用其专有的 AOC 平台，Avidity 首次成功实现了 RNA 在肌肉中的靶向递送，并在三种罕见肌肉疾病的临床开发项目中处于领先地位：肌强直性营养不良症 1 型（DM1）、杜氏肌营养不良症（DMD）和面肩肱肌营养不良症（FSHD）。Avidity 还在推进两个全资拥有的精准心脏病开发候选药物，以应对罕见的遗传性心肌病。此外，Avidity 正在通过关键合作伙伴关系扩大 AOCs 的应用范围，推进和扩展其在心脏病和免疫学领域的管线。Avidity 总部位于加利福尼亚州圣地亚哥。有关我们 AOC 平台、临床开发管线和团队的更多信息，请访问 www.aviditybiosciences.com，并在 LinkedIn 和 X 上与我们互动。</p>
<p><strong>更多信息及获取途径</strong></p>
<p>关于 Avidity 与诺华制药（&#34;Novartis&#34;）之间的拟议交易，Avidity 于 2026 年 1 月 30 日向证券交易委员会（&#34;SEC&#34;）提交了最终代理声明（&#34;代理声明&#34;）。Avidity 可能还会向 SEC 提交其他与拟议交易相关的文件。此文件并不能替代代理声明或 Avidity 可能向 SEC 提交的任何其他文件。Avidity 的股东被敦促全面阅读最终代理声明及诺华和 Avidity 在与交易相关的任何其他文件，因为这些文件包含有关拟议交易及交易各方的重要信息。投资者和证券持有人可以通过 SEC 维护的网站 www.sec.gov 获取代理声明及其他包含有关诺华和 Avidity 的重要信息的文件的免费副本。诺华和 Avidity 在各自的网站上免费提供其向 SEC 提交或提供的文件副本，诺华的网站为 www.novartis.com/investors/financial-data/sec-filings，Avidity 的网站为 investors.aviditybiosciences.com/sec-filings。上述网站的内容不应被视为纳入代理声明的参考。</p>
<p><strong>征求参与者</strong></p>
<p>Avidity 及其部分董事和高管可能被视为参与拟议交易的代理征求。Avidity 的股东可以通过阅读代理声明及与交易相关的任何其他相关文件，获取有关参与者在代理征求中的直接和间接利益的更多信息，包括 Avidity 董事和高管在交易中的利益，这可能与 Avidity 股东的利益不同。您可以使用上述来源获取这些文件的免费副本。</p>
<p><strong>无报价或征求</strong></p>
<p>本通讯仅供信息参考，不构成或不形成任何报价、邀请或征求购买、获取、认购、出售或以其他方式处置任何证券的邀请，或在任何司法管辖区内根据拟议交易或其他情况征求任何投票或批准，也不应在任何司法管辖区内出售、发行或转让证券，违反适用法律。</p>
<p><strong>前瞻性声明</strong></p>
<p>本通讯包含根据 1995 年美国私人证券诉讼改革法案的定义的前瞻性陈述。前瞻性陈述通常可以通过诸如 “潜在的”、“可以”、“将”、“计划”、“可能”、“能够”、“会”、“期望”、“预期”、“期待”、“相信”、“承诺”、“研究性”、“管道”、“推出” 或类似术语，或通过对拟议的合并和分拆（统称为 “交易”）的明确或隐含讨论、完成每项拟议交易的预期时间表及相关的中间步骤、分拆后 SpinCo 和 Avidity 将持有的资产和负债的组成、SpinCo 的管理团队及其现金余额、潜在的市场批准、Avidity 产品候选的新的适应症或标签、Avidity 的平台和临床前资产，或 Avidity 产品候选的潜在未来收入来识别。您不应对这些陈述过于依赖。这些前瞻性陈述基于我们对未来事件的当前信念和期望，并受到重大已知和未知风险和不确定性的影响。如果这些风险或不确定性中的一个或多个实现，或者基础假设被证明不正确，实际结果可能与前瞻性陈述中所列的结果有重大差异。无法保证 Avidity 的研究产品将在任何市场上或在任何特定时间提交或获得销售或任何额外适应症或标签的批准，或者 Avidity 基于其 AOC™平台的产品候选的发现和开发方法将产生任何具有商业价值的产品。无法保证交易的完成条件将在预期时间表上或根本上得到满足，或者交易的预期利益或协同效应将在预期时间内实现，或者根本上实现。特别是，关于 Avidity、SpinCo 或交易的预期可能受到以下因素的影响，包括满足惯例关闭条件的时间，包括获得监管批准和 Avidity 股东的批准，是否在可接受的条款下或根本上；与 SpinCo 分拆实施相关的风险和成本，包括在预期时间内完成分拆的能力，或根本上，以及如果实施，分拆中包含的业务配置的任何变化；根据第三方优先谈判权出售 SpinCo 的某些资产；竞争性报价或收购提案可能会出现的风险；交易带来的干扰影响以及交易公告和待决对诺华和/或 Avidity 业务的影响，包括与员工、商业伙伴或政府实体的关系；交易完成的成本可能比预期更高的风险；与交易相关的股东诉讼可能导致显著的辩护、赔偿和责任成本的风险；由于交易或其他原因，管理层的注意力可能会从持续的业务运营和机会中转移；研究和开发固有的不确定性，包括临床试验结果和对现有临床数据的进一步分析；监管行动或延迟或政府监管的一般风险；以及诺华制药最近的 2024 年 12 月 31 日结束的 20-F 表格年度报告、Avidity 的 2024 年 12 月 31 日结束的 10-K 表格年度报告以及 2025 年 3 月 31 日、2025 年 6 月 30 日和 2025 年 9 月 30 日结束的 10-Q 表格季度报告中提到的风险和因素，以及任何一方随后向 SEC 提交的文件，这些文件可在 SEC 网站 www.sec.gov 上获得，Avidity 在本通讯中提供的信息截至本日期，并不承担因新信息、未来事件或其他原因更新本通讯中包含的任何前瞻性陈述的义务，除非法律要求。</p>
<p>媒体联系人：</p>
<p>Kristina Coppola</p>
<p>(619) 837-5016</p>
<p>media@aviditybio.com</p>
<p>来源：Avidity Biosciences, Inc.</p>

诺华制药

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普全球医疗股指数 ETF - iShares

IBBQ

标普生物技术 ETF - SPDR

医疗业 ETF - Vanguard

标普生物技术 3 倍做空 - Direxion

<p>Avidity Biosciences, Inc. 宣布，2026 年 2 月 12 日将是向 Avidity 股东分配 Atrium Therapeutics, Inc. 股票的记录日期，此举是与诺华制药的收购相关的分拆的一部分。股东将每持有十股 Avidity 股票即可获得一股 Atrium 股票。合并和分拆的完成需满足某些条件，包括股东批准。Avidity 专注于 RNA 治疗，拥有针对罕见肌肉疾病和遗传性心肌病的产品线</p>

<p>, /PRNewswire/ -- Avidity Biosciences, Inc. (&#34;Avidity&#34;) (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (&#34;AOCs™&#34;) to profoundly improve people's lives, today announced that its board of directors has designated the close of business, Eastern Time, on February 12, 2026 as the record date (the &#34;Record Date&#34;) for the pro rata distribution of all of the issued and outstanding shares of common stock of Atrium Therapeutics, Inc. (&#34;SpinCo&#34;) to holders of Avidity common stock on the Record Date in connection with the previously announced proposed acquisition of Avidity by Novartis AG (the &#34;Merger&#34;) and the separation of Avidity's early-stage precision cardiology programs into SpinCo (the &#34;Spin-Off&#34;). Each such holder will receive one share of SpinCo common stock for every ten shares of Avidity common stock held on the Record Date.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Avidity Biosciences, Inc.（&#34;Avidity&#34;）（纳斯达克：RNA）是一家生物制药公司，致力于提供一种新的 RNA 治疗药物类别，称为抗体寡核苷酸结合物（&#34;AOCs™&#34;），以深刻改善人们的生活。今天宣布，其董事会已指定 2026 年 2 月 12 日东部时间营业结束时为记录日期（&#34;记录日期&#34;），用于按比例分配 Atrium Therapeutics, Inc.（&#34;SpinCo&#34;）所有已发行和流通的普通股给在记录日期持有 Avidity 普通股的股东，这与之前宣布的 Avidity 被诺华制药（&#34;Merger&#34;）收购的提议以及将 Avidity 的早期精准心脏病项目分拆到 SpinCo（&#34;Spin-Off&#34;）有关。每位股东将在记录日期持有的每十股 Avidity 普通股中获得一股 SpinCo 普通股。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/974628/Avidity_Biosciences_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/974628/Avidity_Biosciences_Logo.jpg"/></p>
<p>Completion of the Merger and of the Spin-Off remain subject to certain closing conditions noted in Avidity's definitive proxy statement filed with the Securities and Exchange Commission on January 30, 2026, including the receipt of Avidity stockholder approval. Accordingly, the Record Date may change based on the closing date of the Merger and the Spin-Off.</p>
<div class="lb-trans"><p>合并和分拆的完成仍需满足 Avidity 于 2026 年 1 月 30 日向证券交易委员会提交的最终代理声明中提到的某些成交条件，包括获得 Avidity 股东的批准。因此，记录日期可能会根据合并和分拆的成交日期而变化。</p>
</div><p><strong>About Avidity</strong></p>
<div class="lb-trans"><p><strong>关于 Avidity</strong></p>
</div><p>Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and X.</p>
<div class="lb-trans"><p>Avidity Biosciences, Inc.的使命是通过提供一种新的 RNA 治疗药物类别——抗体寡核苷酸结合物（AOCs™）来深刻改善人们的生活。Avidity 正在通过其专有的 AOCs 革命性地改变 RNA 领域，这些 AOCs 旨在将单克隆抗体的特异性与寡核苷酸疗法的精准性结合起来，以应对以前无法通过现有 RNA 疗法达到的靶点和疾病。利用其专有的 AOC 平台，Avidity 首次成功实现了 RNA 在肌肉中的靶向递送，并在三种罕见肌肉疾病的临床开发项目中处于领先地位：肌强直性营养不良症 1 型（DM1）、杜氏肌营养不良症（DMD）和面肩肱肌营养不良症（FSHD）。Avidity 还在推进两个全资拥有的精准心脏病开发候选药物，以应对罕见的遗传性心肌病。此外，Avidity 正在通过关键合作伙伴关系扩大 AOCs 的应用范围，推进和扩展其在心脏病和免疫学领域的管线。Avidity 总部位于加利福尼亚州圣地亚哥。有关我们 AOC 平台、临床开发管线和团队的更多信息，请访问 www.aviditybiosciences.com，并在 LinkedIn 和 X 上与我们互动。</p>
</div><p><strong>Additional information and Where to Find It</strong></p>
<div class="lb-trans"><p><strong>更多信息及获取途径</strong></p>
</div><p>In connection with the proposed transaction between Avidity and Novartis AG (&#34;Novartis&#34;), Avidity has filed with the Securities and Exchange Commission (the &#34;SEC&#34;) a definitive proxy statement on January 30, 2026 (the &#34;Proxy Statement&#34;). Avidity may also file other documents with the SEC regarding the proposed transaction. This document is not a substitute for the Proxy Statement or any other document that may be filed by Avidity with the SEC. AVIDITY'S STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT IN ITS ENTIRETY AND ANY OTHER DOCUMENTS FILED BY EACH OF NOVARTIS AND AVIDITY WITH THE SEC IN CONNECTION WITH THE TRANSACTIONS OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTIONS AND THE PARTIES TO THE PROPOSED TRANSACTIONS. Investors and security holders are able to obtain a free copy of the Proxy Statement and such other documents containing important information about Novartis and Avidity through the website maintained by the SEC at www.sec.gov. Novartis and Avidity make available free of charge at the Novartis website at www.novartis.com/investors/financial-data/sec-filings and Avidity's website at investors.aviditybiosciences.com/sec-filings, respectively, copies of documents they file with, or furnish to, the SEC. The contents of the websites referenced above will not be deemed to be incorporated by reference into the Proxy Statement.</p>
<div class="lb-trans"><p>关于 Avidity 与诺华制药（&#34;Novartis&#34;）之间的拟议交易，Avidity 于 2026 年 1 月 30 日向证券交易委员会（&#34;SEC&#34;）提交了最终代理声明（&#34;代理声明&#34;）。Avidity 可能还会向 SEC 提交其他与拟议交易相关的文件。此文件并不能替代代理声明或 Avidity 可能向 SEC 提交的任何其他文件。Avidity 的股东被敦促全面阅读最终代理声明及诺华和 Avidity 在与交易相关的任何其他文件，因为这些文件包含有关拟议交易及交易各方的重要信息。投资者和证券持有人可以通过 SEC 维护的网站 www.sec.gov 获取代理声明及其他包含有关诺华和 Avidity 的重要信息的文件的免费副本。诺华和 Avidity 在各自的网站上免费提供其向 SEC 提交或提供的文件副本，诺华的网站为 www.novartis.com/investors/financial-data/sec-filings，Avidity 的网站为 investors.aviditybiosciences.com/sec-filings。上述网站的内容不应被视为纳入代理声明的参考。</p>
</div><p><strong>Participants in the Solicitation</strong></p>
<div class="lb-trans"><p><strong>征求参与者</strong></p>
</div><p>Avidity and certain of its respective directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Avidity stockholders may obtain additional information regarding the direct and indirect interests of the participants in the solicitation of proxies in connection with the proposed transaction, including the interests of Avidity directors and executive officers in the transaction, which may be different than those of Avidity stockholders generally, by reading the Proxy Statement and any other relevant documents that are filed or will be filed with the SEC relating to the transaction. You may obtain free copies of these documents using the sources indicated above.</p>
<div class="lb-trans"><p>Avidity 及其部分董事和高管可能被视为参与拟议交易的代理征求。Avidity 的股东可以通过阅读代理声明及与交易相关的任何其他相关文件，获取有关参与者在代理征求中的直接和间接利益的更多信息，包括 Avidity 董事和高管在交易中的利益，这可能与 Avidity 股东的利益不同。您可以使用上述来源获取这些文件的免费副本。</p>
</div><p><strong>No Offer or Solicitation</strong></p>
<div class="lb-trans"><p><strong>无报价或征求</strong></p>
</div><p>This communication is for informational purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.</p>
<div class="lb-trans"><p>本通讯仅供信息参考，不构成或不形成任何报价、邀请或征求购买、获取、认购、出售或以其他方式处置任何证券的邀请，或在任何司法管辖区内根据拟议交易或其他情况征求任何投票或批准，也不应在任何司法管辖区内出售、发行或转让证券，违反适用法律。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This communication contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as &#34;potential,&#34; &#34;can,&#34; &#34;will,&#34; &#34;plan,&#34; &#34;may,&#34; &#34;could,&#34; &#34;would,&#34; &#34;expect,&#34; &#34;anticipate,&#34; &#34;look forward,&#34; &#34;believe,&#34; &#34;committed,&#34; &#34;investigational,&#34; &#34;pipeline,&#34; &#34;launch,&#34; or similar terms, or by express or implied discussions regarding the proposed Merger and the Spin-Off (collectively, the &#34;Transactions&#34;), the expected timetable for completing each of the proposed Transactions and the related interim steps, the composition of the assets and liabilities to be held by SpinCo and Avidity following the Spin-Off, the management team for SpinCo and its cash balance, potential marketing approvals, new indications or labeling for Avidity's product candidates, Avidity's platform and preclinical assets, or potential future revenues from Avidity's product candidates. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Avidity's investigational products will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time, or that Avidity's approach to the discovery and development of product candidates based on its AOC™ platform will produce any products of commercial value. There can be no guarantee that the conditions to the closing of the Transactions will be satisfied on the expected timetable or at all or that the expected benefits or synergies from the Transactions will be achieved in the expected timeframe, or at all. In particular, expectations regarding Avidity, SpinCo, or the Transactions could be affected by, among other things, the timing of the satisfaction of customary closing conditions, including the receipt of regulatory approvals and the approval of Avidity's stockholders, on acceptable terms or at all; risks and costs related to the implementation of the separation of SpinCo, including the ability to complete the separation in the anticipated timeframe, or at all, and any changes to the configuration of the businesses included in the separation if implemented; the sale of certain of SpinCo's assets pursuant to a third party right of first negotiation; the risk that competing offers or acquisition proposals will be made; the effects of disruption from the Transactions and the impact of the announcement and pendency of the Transactions on Novartis' and/or Avidity's businesses, including their relationships with employees, business partners or governmental entities; the risk that the Transactions may be more expensive to complete than anticipated; the risk that stockholder litigation in connection with the Transactions may result in significant costs of defense, indemnification and liability; a diversion of management's attention from ongoing business operations and opportunities as a result of the Transactions or otherwise; the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; and the risks and factors referred to in Novartis AG's most recent Annual Report on Form 20-F for the year ended December 31, 2024, Avidity's Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, June 30, 2025 and September 30, 2025, and any subsequent filings made by either party with the SEC, available on the SEC's website at www.sec.gov, Avidity is providing the information in this communication as of this date and does not undertake any obligation to update any forward-looking statements contained in this communication as a result of new information, future events or otherwise, except to the extent required by law.</p>
<div class="lb-trans"><p>本通讯包含根据 1995 年美国私人证券诉讼改革法案的定义的前瞻性陈述。前瞻性陈述通常可以通过诸如 “潜在的”、“可以”、“将”、“计划”、“可能”、“能够”、“会”、“期望”、“预期”、“期待”、“相信”、“承诺”、“研究性”、“管道”、“推出” 或类似术语，或通过对拟议的合并和分拆（统称为 “交易”）的明确或隐含讨论、完成每项拟议交易的预期时间表及相关的中间步骤、分拆后 SpinCo 和 Avidity 将持有的资产和负债的组成、SpinCo 的管理团队及其现金余额、潜在的市场批准、Avidity 产品候选的新的适应症或标签、Avidity 的平台和临床前资产，或 Avidity 产品候选的潜在未来收入来识别。您不应对这些陈述过于依赖。这些前瞻性陈述基于我们对未来事件的当前信念和期望，并受到重大已知和未知风险和不确定性的影响。如果这些风险或不确定性中的一个或多个实现，或者基础假设被证明不正确，实际结果可能与前瞻性陈述中所列的结果有重大差异。无法保证 Avidity 的研究产品将在任何市场上或在任何特定时间提交或获得销售或任何额外适应症或标签的批准，或者 Avidity 基于其 AOC™平台的产品候选的发现和开发方法将产生任何具有商业价值的产品。无法保证交易的完成条件将在预期时间表上或根本上得到满足，或者交易的预期利益或协同效应将在预期时间内实现，或者根本上实现。特别是，关于 Avidity、SpinCo 或交易的预期可能受到以下因素的影响，包括满足惯例关闭条件的时间，包括获得监管批准和 Avidity 股东的批准，是否在可接受的条款下或根本上；与 SpinCo 分拆实施相关的风险和成本，包括在预期时间内完成分拆的能力，或根本上，以及如果实施，分拆中包含的业务配置的任何变化；根据第三方优先谈判权出售 SpinCo 的某些资产；竞争性报价或收购提案可能会出现的风险；交易带来的干扰影响以及交易公告和待决对诺华和/或 Avidity 业务的影响，包括与员工、商业伙伴或政府实体的关系；交易完成的成本可能比预期更高的风险；与交易相关的股东诉讼可能导致显著的辩护、赔偿和责任成本的风险；由于交易或其他原因，管理层的注意力可能会从持续的业务运营和机会中转移；研究和开发固有的不确定性，包括临床试验结果和对现有临床数据的进一步分析；监管行动或延迟或政府监管的一般风险；以及诺华制药最近的 2024 年 12 月 31 日结束的 20-F 表格年度报告、Avidity 的 2024 年 12 月 31 日结束的 10-K 表格年度报告以及 2025 年 3 月 31 日、2025 年 6 月 30 日和 2025 年 9 月 30 日结束的 10-Q 表格季度报告中提到的风险和因素，以及任何一方随后向 SEC 提交的文件，这些文件可在 SEC 网站 www.sec.gov 上获得，Avidity 在本通讯中提供的信息截至本日期，并不承担因新信息、未来事件或其他原因更新本通讯中包含的任何前瞻性陈述的义务，除非法律要求。</p>
</div><p>Media Contact:</p>
<div class="lb-trans"><p>媒体联系人：</p>
</div><p>Kristina Coppola</p>
<div class="lb-trans"><p>Kristina Coppola</p>
</div><p>(619) 837-5016</p>
<div class="lb-trans"><p>(619) 837-5016</p>
</div><p>media@aviditybio.com</p>
<div class="lb-trans"><p>media@aviditybio.com</p>
</div><p>SOURCE Avidity Biosciences, Inc.</p>
<div class="lb-trans"><p>来源：Avidity Biosciences, Inc.</p>
</div>

Avidity Biosciences Announces Expected Record Date for Spin-Off | RNA Stock News

StockTitan

Invesco Nasdaq Biotechnology ETF

Atrium Therapeutics

Avidity Biosciences 宣布分拆的预期记录日期 | RNA 股票新闻